Noteworthy, patients who had low baseline CD8+ T-cell infiltration and received pembrolizumab alone also had lower levels of viable tumor cells in their specimens when compared with those who received canakinumab alone, raising questions on the potential synergistic antitumor effect generated by the addition of canakinumab in these patients. The gene discussed is CD8A; the disease is neoplasm.